Navigation Links
PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
Date:6/1/2009

tements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN(R) is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
2. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
4. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
5. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
6. Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies) Conference
7. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
8. Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
9. Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
10. Pulmo BioTech Inc. Announces Paper to be Presented at Symposium
11. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:10/1/2014)... 30, 2014 This report analyzes ... US$ Million by the following Product Segments: ... Specific end-use segments also analyzed are Pharmaceuticals ... The report provides separate comprehensive analytics for ... East, and Latin America. Annual estimates and ...
(Date:9/30/2014)... release is available in German . ... around several quantum dots in a semiconductor layer. Quantum dots ... of atomic processes. If a short laser pulse is fired ... the quantum dot experiences a change in the electromagnetic field ... the emission of light by the dot. As soon as ...
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26Ultrafast remote switching of light emission 2A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3
... SEATTLE, March 8, 2011 Cell Therapeutics, Inc. (CTI) ... present at the Bio Europe Spring 2011 Conference on ... 1, room Yellow 2, at Milano Convention Centre, Milan, ... PM CET /10:30 AM EST/ 7.30 AM PSTRoom Yellow ...
... NEW YORK, March 7, 2011 Reportlinker.com ... is available in its catalogue: ... strategic assessment of the competitive environment is ... priority management responsibilities, the task crucial to ...
... Reportlinker.com announces that a new market ... The 2011 Blood Banking ... and Business Expansion Strategies for Suppliers ... During the next ten years, the blood ...
Cached Biology Technology:Reportlinker Adds The 2011 Top Ten World's Leading Life Science Intermediates Companies 2Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers 2
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
(Date:9/30/2014)... and farm runoff in Hawaii is causing tumors in ... The study, published Tuesday in the peer-reviewed open-access journal ... ends up in algae that the turtles eat, promoting ... and internal organs. , Scientists at Duke University, the ... Administration (NOAA) conducted the study to better understand the ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... Despite dozens of interceptions at U.S. ports, a public enemy ... N.Y., and identified by a Cornell University expert, the adult ... discovered in the eastern United States. , The discovery of ... woodwasp, raises red flags across the nation because the invasive ...
... study in the April issue (currently available online) ... take scientists closer to understanding how cells in ... Researchers, led by Anthony Firulli, Ph.D., associate professor ... at the Indiana University School of Medicine, investigated ...
... to happen - you being in a car wreck or being ... greater killers win a free trip to the beach. It's really ... being in a wreck are far greater than being a shark's ... who has studied sharks for years. , Worldwide, about one million ...
Cached Biology News:Alien woodwasp, threat to US pine trees, found in N.Y. 2Determining The Fate Of Cells In The Human Body 2New HIV drug candidate developed in Sweden 2